Company / PP&E (Net)
Amylyx Pharmaceuticals, Inc. PP&E (Net) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$310.0K
FY2025
5-year range
$310.0K / $2.7M
FY2021-FY2025
Trend
-67.7%
vs FY2024
Sector context
#175 of 193
Health Care
What the data says
Among 193 Health Care companies, Amylyx Pharmaceuticals, Inc. is in the bottom 9% for pp&e (net). Declined from $3M to $310,000 over the past 2 years.
Based on SEC 10-K filings.
$310,000 in FY2025 with a 3-year CAGR of -50.9%.
Declined from $3M to $310,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -50.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 193This company $310.0K Sector average $777.6M
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -50.9%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 67.7% year-over-year.
- Ranks #175 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $310.0K | -67.7% |
| FY2024 | $961.0K | -64.2% |
| FY2023 | $2.7M | +2.9% |
| FY2022 | $2.6M | +450.8% |
| FY2021 | $474.0K | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026